Cargando…

Achievement of long-term local control after radiation and anti-PD-1 immunotherapy in locally advanced non-small cell lung cancer

Although concurrent chemoradiotherapy (CRT) is recommended as standard of care in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC), many patients who refuse or are not eligible for chemotherapy received radiotherapy (RT) alone with 5-year overall survival (O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jing, Zhao, Zhou, Rongjin, Zhang, Ni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482707/ https://www.ncbi.nlm.nih.gov/pubmed/34729152 http://dx.doi.org/10.1177/20406223211047306

Ejemplares similares

Long-term Survival of Locally Advanced Stage III Non-small Cell Lung Cancer Patients Treated with Chemoradiotherapy and Perspectives for The Treatment with Immunotherapy
por: Vrankar, Martina, et al.
Publicado: (2018)

Neoadjuvant therapy for locally advanced non-small cell lung cancer: TKIs or immunotherapy?
por: Zhang, Zhenyang, et al.
Publicado: (2020)

Expert consensus on perioperative immunotherapy for locally advanced non-small cell lung cancer
por: Lim, Jeong Uk, et al.
Publicado: (2021)

Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
por: Qiu, Bin, et al.
Publicado: (2021)

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy
por: Chatziioannou, Eftychia, et al.
Publicado: (2023)

Metabolic targeting, immunotherapy and radiation in locally advanced non-small cell lung cancer: Where do we go from here?
por: Dhawan, Annika, et al.
Publicado: (2022)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
por: Zhang, Xiaofei, et al.
Publicado: (2023)

Factors predicting radiation pneumonitis in locally advanced non-small cell lung cancer
por: Kim, Myungsoo, et al.
Publicado: (2011)

The Long-Term Outcomes of Induction Chemoradiotherapy Followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer
por: Uramoto, Hidetaka, et al.
Publicado: (2014)

Long‐term survival in locally advanced non‐small cell lung cancer invading the great vessels and heart
por: Park, Byungjoon, et al.
Publicado: (2018)

Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy
por: Zeng, Xianghua, et al.
Publicado: (2020)

Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature
por: Franzi, Sara, et al.
Publicado: (2022)

Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer
por: Ran, Juntao, et al.
Publicado: (2017)

Radiotherapy for unresectable locally advanced non-small cell lung cancer: a narrative review of the current landscape and future prospects in the era of immunotherapy
por: Guo, Tiantian, et al.
Publicado: (2020)

A narrative review of toxicity of chemoradiation and immunotherapy for unresectable, locally advanced non-small cell lung cancer
por: Prasad, Rahul N., et al.
Publicado: (2020)

Neoadjuvant immunotherapy combined with chemotherapy for local advanced non-small cell lung cancer: a case report
por: Yang, Jie, et al.
Publicado: (2021)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma
por: Ghali, Fady, et al.
Publicado: (2019)

Hypofractionation and Stereotactic Body Radiation Therapy in Inoperable Locally Advanced Non-small Cell Lung Cancer
por: Rico, Mikel, et al.
Publicado: (2021)

FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
por: Liu, Jiaxin, et al.
Publicado: (2022)

Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Brito, Angelo Borsarelli Carvalho, et al.
Publicado: (2021)

Late Local Urticaria as a Long-term Sequela of Allergen-Specific Immunotherapy
por: Choi, Inseon S, et al.
Publicado: (2004)

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
por: Dantoing, Edouard, et al.
Publicado: (2021)

The power of immunotherapy plus platinum–based chemotherapy for locally advanced or early stage non-small cell lung cancer
por: Hofman, Paul
Publicado: (2020)

A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy
por: Li, Shuyan, et al.
Publicado: (2020)

Has the practice of radiation oncology for locally advanced and metastatic non-small-cell lung cancer changed in Canada?
por: Han, K., et al.
Publicado: (2010)

Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer
por: Karam, Sana D, et al.
Publicado: (2013)

The use of dose-escalated radiation for locally advanced non-small cell lung cancer in the U.S., 2004–2013
por: Christodouleas, John P., et al.
Publicado: (2017)

Locally Advanced Non Small Cell Lung Cancer: The Case for Radiation Dose De-escalation in the Management of the Mediastinum
por: Soyfer, Viacheslav, et al.
Publicado: (2019)

Long-Term Outcomes of Local Excision Following Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
por: D’Alimonte, Lucrezia, et al.
Publicado: (2020)

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients
por: Rogala, Paweł, et al.
Publicado: (2022)

Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
por: Sahni, Sakshi, et al.
Publicado: (2018)

Volumetric modulated arc therapy for lung stereotactic radiation therapy can achieve high local control rates
por: Yamashita, Hideomi, et al.
Publicado: (2014)

Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer
por: Boyle, John, et al.
Publicado: (2017)

Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancer
por: Yegya-Raman, Nikhil, et al.
Publicado: (2023)

Predicting development of distant metastases and long-term outcome of locally advanced rectal cancer treated with neoadjuvant chemotherapy and radiation
por: Aschele, Carlo, et al.
Publicado: (2022)

Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
por: Inoue, Hiroto, et al.
Publicado: (2020)

Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials
por: Ramos-Esquivel, Allan, et al.
Publicado: (2017)

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
por: de Jong, Florus C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ov0tfmls1ltq793grg6mqp0jan